Astellas Secures Option on Audax IL-12 Drug in $1.34B Deal
Image
TOKYO – October 29, 2026 -- Astellas Pharma Inc. has secured an exclusive option on a worldwide license to Audax Biosciences' immuno-oncology candidate DAX-044 in a transaction worth up to US$1.34 billion, excluding royalties.
Audax receives US$285 million up front and on option exercise
Audax will receive US$285 million in combined up-front and option-exercise payments. It is also eligible for development and commercial milestones of up to US$1.05 billion, plus tiered double-digit royalties on worldwide net sales if DAX-044 is approved.
Audax carries the program into a Phase 1 study expected to start in 2027. DAX-044 is currently in IND/CTN-enabling development.